Efficacy and clinical analysis of ceritinib/ceritinib (Zanda) in ROS1-positive patients

Ceritinib (Ceritinib) is a targeted therapy drug, mainly used to treat ALK non-small cell lung cancer (NSCLC) with positive gene rearrangement. In recent years, studies have found that it also has a certain effect on NSCLC patients with positive ROS1 gene rearrangements. ROS1gene rearrangement accounts for approximately 1% to 2% of non-small cell lung cancer, and mainly occurs in young patients with no history of smoking. Due to limited treatment options for ROS1positive lung cancer, ceritinib has received widespread attention as a potential treatment option.

In an open-label, multicenter Phase II clinical study, researchers evaluated the efficacy of ceritinib in patients with ROS1 rearrangement-positive non-small cell lung cancer. The study results showed that ceritinib had significant anti-tumor activity in these patients. Among crizotinib-naive patients, the median progression-free survival (PFS) was 19.3 months, and among all patients, the median PFS was 9.3 months. In addition, ceritinib achieved an intracranial disease control rate of 63% in patients with brain metastases, demonstrating its penetration into the central nervous system. Common adverse reactions include diarrhea, nausea and loss of appetite, most of which are grade 1 or grade 2.

Although ceritinib has shown promising efficacy in ROS1positive non-small cell lung cancer patients, its use in this population is still in the investigational stage. Currently, ceritinib has not been officially approved for ROS1 rearrangement-positive lung cancer and has not been included in treatment guidelines in many countries and regions. Therefore, patients should fully discuss the potential benefits and risks with their oncologist before considering treatment with ceritinib.

In summary, ceritinib, as an ALK inhibitor, showed significant effects on ROS1Potential efficacy in patients with positive non-small cell lung cancer. Although preliminary study results are encouraging, more clinical data are needed to verify its long-term efficacy and safety. When choosing a treatment option, patients should work closely with a professional medical team to develop an individualized treatment plan.

Reference materials:https://www.drugs.com/